Spero Therapeutics Inc SPRO.OQ SPRO.O is expected to show a fall in quarterly revenue when it reports results on August 12 for the period ending June 30 2025
LSEG's mean analyst estimate for Spero Therapeutics Inc is for a loss of 38 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Spero Therapeutics Inc is $5.00, about 56.6% above its last closing price of $2.17
This summary was machine generated August 8 at 21:58 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)